香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」）之 董 事（「董 事」）會（「董事會」）宣 佈，鄭 章 勁 先 生（「鄭先生」）辭 任(1)本 公 司 之 公 司 秘 書、(2)香 港 聯 合 交 易 所 有 限 公 司（「聯 交 所」）證 券 上 市 規 則（「上市規則」）第3.05條 項 下 本 公 司 之 授 權 代 表（「授權代表」） 及(3)上市規則第19.05(2)條 及 公 司 條 例（香 港 法 例 第622章）第16部項下代表本公 司 於 香 港 接 收 法 律 程 序 文 件 及 通 知 之 代 理 人（「法律程序代理人」），自 二 零 二 五 年 十 月 十 七 日 起 生 效（「辭 任」）。鄭 先 生 確 認 彼 與 董 事 會 並 無 任 何 意 見 分 歧，亦 無 任 何 有 關 彼 辭 任 之 事 宜 須 ...

（於開曼群島註冊成立之有限公司） （股份代號：1011） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 有關截至2024年12月31日止年度之年報所載 持續經營之不發表意見的最新信息 茲 提 述 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 所刊發截至2024年12月31日 止 年 度 之 年 報（「年 報」）所 載 有 關 僅 針 對 持 續 經 營 問 題 之 不 發 表 意 見 提 供 最 新 信 息。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 年 報 所 界 定 者 具 有 相 同 涵 義。 受 中 國 醫 藥 行 業 發 展 新 趨 勢 及 產 業 政 策 改 革 影 響，本 公 司 董 事 會 從2020年起開 始 陸 續 處 置 集 團 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01011 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 62,592,500,000 | USD | | 0.0000008 | USD | | 50,074 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 62,592,500,000 | USD | | 0.0000008 | USD | | 50,074 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | -- ...

China NT Pharma Group Company Limited 中國泰凌醫藥集團有限公司 (incorporated in Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 1011) NOTIFICATION LETTER 通知信函 5 September 2025 Dear Non-registered Holder(s)(Note 1) China NT Pharma Group Company Limited (the "Company") – Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.ntpharm ...

China NT Pharma Group Company Limited Dear Registered Shareholders, China NT Pharma Group Company Limited (the "Company") – Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.ntpharma.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company ...

Financial Performance - Total revenue for the six months ended June 30, 2025, was approximately RMB 12.0 million, a decrease of RMB 19.3 million or 61.7% compared to RMB 31.3 million in the same period of 2024[6][9] - The company recorded a loss of approximately RMB 16.9 million during the review period, a decrease of RMB 15.6 million compared to a profit of RMB 0.7 million in the same period of 2024[6][14] - Gross profit for the review period was approximately RMB 10.0 million, a decrease of RMB 4.3 million or 75.5% compared to RMB 5.7 million in the same period of 2024[11] - Revenue for the six months ended June 30, 2025, was RMB 11,995,000, a decrease of 61.7% compared to RMB 31,297,000 for the same period in 2024[59] - The company reported a net loss of RMB 16,906,000 for the period, compared to a profit of RMB 661,000 in 2024[60] - The group reported a net loss of approximately RMB 16,906,000 for the six months ended June 30, 2025[68] - The group incurred a loss before tax of RMB 16,906,000 for the six months ended June 30, 2025[77] Cost and Expenses - Cost of sales for the review period was approximately RMB 2.0 million, a decrease of RMB 23.6 million or 92.3% compared to RMB 25.6 million in the same period of 2024[10] - Financing costs increased to approximately RMB 14.6 million, an increase of RMB 8.6 million or 143.1% compared to RMB 6.0 million in the same period of 2024[12] - The total cost for employee compensation, benefits, and social security for the six months ended June 30, 2025, is approximately RMB 5.2 million[36] - The total short-term employee benefits for key management personnel for the six months ended June 30, 2025, amounted to RMB 878,000, a decrease from RMB 891,000 in the same period of 2024[115] Debt and Liabilities - Total debt as of June 30, 2025, was approximately RMB 449.7 million, a decrease from RMB 552.9 million as of December 31, 2024[18] - Net debt as of June 30, 2025, was approximately RMB 445.1 million, down from RMB 543.3 million as of December 31, 2024[18] - The total liabilities as of June 30, 2025, amounted to approximately RMB 592,693,000, with net liabilities at RMB 276,877,000[68] - Total liabilities, including trade and other payables, amounted to RMB 171,556,000 as of June 30, 2025, compared to RMB 180,221,000 at the end of 2024[92] Share Capital and Equity - The total number of issued shares as of June 30, 2025, is 674,246,015, with no consideration for any unexercised options or convertible preferred shares[50] - The company has agreed to issue 410,156,509 new shares to repay part of the outstanding principal and accrued interest amounting to HKD 87,000,000 and approximately RMB 44,000,000 for the release of the financial guarantee contract[20] - The company completed the capitalization of loans on February 21, 2025, agreeing to issue 146,520,146 new shares, which relates to the release of the financial guarantee contract[21] - The total issued share capital as of June 30, 2025, was 674,246,000 shares, following a share consolidation that reduced the total from 2,640,895,000 shares[102] Business Strategy and Future Plans - The company plans to expand its business through acquisitions in the field of AI bone health diagnostic and testing robots, and to establish a smart health management center in collaboration with a state-owned enterprise in China[7] - The company aims to create a closed-loop business model in the bone health sector, focusing on detection, treatment, and rehabilitation services[7] - The group aims to develop a comprehensive smart health ecosystem platform focusing on bone health, including diagnostic and treatment services[71] Financial Guarantees and Claims - The company has provided financial guarantees for bank loans amounting to approximately RMB 348,073,000 and RMB 58,030,000 for its subsidiary Suzhou First Pharmaceutical Co., Ltd.[20] - As of June 30, 2025, the company has not faced any claims from lenders regarding the financial guarantees[25] - The company has confirmed that there are no other individuals holding significant interests in the company's shares as of June 30, 2025, apart from those disclosed[52] Cash Flow and Assets - Cash and cash equivalents at the end of the period were RMB 4,634,000, down from RMB 9,623,000 at the beginning of the year[63] - The company experienced a net cash outflow from operating activities of RMB 19,236,000, compared to RMB 5,741,000 in the previous year[63] - Total assets decreased to RMB 28,219,000 from RMB 16,185,000, while total liabilities decreased from RMB 725,065,000 to RMB 620,912,000[61] Shareholder Information - The major shareholders include Golden Base Investment Limited, holding 303,925,563 shares, representing approximately 45.12% of the company's equity[50] - The company has not proposed any interim dividend for the six months ended June 30, 2025[42] - The company did not declare or pay any dividends for the six months ended June 30, 2025, consistent with the previous year[101] Audit and Compliance - The audit committee reviewed the unaudited interim results for the six months ending June 30, 2025, and recommended adoption by the board, confirming compliance with applicable accounting standards and listing rules[44] - The company maintains a sufficient public float, with over 25% of its issued share capital held by the public as of the report date[45]

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01011 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 62,592,500,000 | USD | | 0.0000008 | USD | | 50,074 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 62,592,500,000 | USD | | 0.0000008 | USD | | 50,074 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A ...

Core Viewpoint - TaiLing Pharmaceutical (01011) resumed trading today, experiencing a significant drop of over 16% at one point, and currently down 8.97% at HKD 0.71, with a trading volume of HKD 2.8566 million [1] Group 1 - The company was temporarily suspended from trading yesterday afternoon and resumed trading this morning [1] - On August 19, the company announced that it received a request from the Hong Kong government to assist in verifying a contract related to an independent third party [1] - The matter does not impact the company's daily operations, and as of the announcement date, the company's directors and senior management have no legal liabilities [1]

Core Viewpoint - 泰凌医药's stock experienced significant volatility upon resuming trading, initially dropping over 16% before stabilizing to a decline of 8.97% at HKD 0.71, with a trading volume of HKD 2.8566 million [1] Group 1 - 泰凌医药 was temporarily suspended from trading prior to its resumption this morning [1] - The company received a request from Hong Kong government authorities to assist in verifying a contract related to an independent third party [1] - The matter raised by the authorities does not impact the company's daily operations [1] Group 2 - As of the announcement date, the company's directors and senior management have no legal liabilities related to the matter [1]

Core Viewpoint - 泰凌医药's shares will resume trading on August 20, 2025, at 9:00 AM [1] Company Summary - 泰凌医药 has announced the resumption of its share trading, indicating a potential return to normal operations and investor interest [1]